Burning Rock Biotech Ltd ADR(BNR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.91 | Insider Own | 0.24% | Shs Outstand | 8.8M | Perf Week | -9.25% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 8.8M | Perf Month | -35.27% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 19.79% | Short Float | 0.42% | Perf Quarter | 38.53% |
| Income | -0.01B | P/S | 1.51 | EPS this Y | - | Inst Trans | 0.47% | Short Ratio | 1.18 | Perf Half Y | -24.51% |
| Sales | 0.07B | P/B | 1.76 | EPS next 5Y | - | ROA | -8.63% | Short Interest | 0.04M | Perf YTD | -39.16% |
| Book/sh | 6.96 | P/C | 1.74 | EPS past 3/5Y | 62.63% 40.8% | ROE | -12.81% | 52W High | -70.61% ($41.72) | Perf Year | - |
| Cash/sh | 7.03 | P/FCF | - | Sales past 3/5Y | -3.55% 3.8% | ROIC | -12.69% | 52W Low | 80.56% ($6.79) | Perf 3Y | 16.21% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 51.3% | Gross Margin | 74.52% | Volatility(W/M) | 14.25% 11.71% | Perf 5Y | -91.48% |
| Dividend TTM | - | EV/Sales | 0.74 | Sales Y/Y TTM | -3.65% | Oper. Margin | -13.02% | ATR (14) | 1.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.87 | EPS Q/Q | -99.84% | Profit Margin | -13.6% | RSI (14) | 43.43 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.03 | Sales Q/Q | -3.6% | SMA20 | -13.04% ($14.1) | Beta | 1.45 | Target Price | $31.65 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/9/10 | SMA50 | -7.03% ($13.19) | Rel Volume | 0.57 | Prev Close | $11.87 |
| Employees | 667 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | - | SMA200 | -26.16% ($16.6) | Avg Volume(3M) | 0.03M | Price | $12.26 |
| IPO | 2020/6/12 | Option/Short | No/Yes | Trades | 356 | Volume | 17,715 | Change | 3.29% |
🧬 A precision oncology diagnostics company that applies next-generation sequencing technology to cancer diagnosis. Its focus is on treatment selection testing for patients with advanced cancer and early cancer detection testing, operating three business segments: central laboratory services, in-hospital services, and pharmaceutical R&D services. It is a micro-cap stock that conducts its business based in the Chinese market.
Over the past 1 year, on the lower side
71% below its 1-year high.
Traded less than usual. That is 57% of its average volume.
BNR has a sound balance sheet but weak earning power
Of every $100 in sales, $13.02 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $151. Peers typically go for $458.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.5%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
EHLS Even Herd Long Short ETF <0.01% 
PGJ Invesco Golden Dragon China ETF <0.01% It ranks #35 of 44 in the industry
Based on market cap of $108M.
BDSX#33 Biodesix Inc $241M PER - 
XGN#34 Exagen Inc $203M PER - BNR#35 Burning Rock Biotech Ltd ADR $108M PER - 
IMDX#36 Insight Molecular Diagnostics Inc $104M PER - 
QUCY#37 Quantum Cyber NV $84M PER - 
FAQ
What kind of company is BNR?
BNR belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of BNR?
The market cap of BNR is approximately $108M, ranking 4,433 within its sector.
What is the 52-week high and low for BNR?
BNR has recorded a 52-week high of $41.72 and a low of $6.79.
